Results 231 to 240 of about 17,710 (254)

Dupilumab

Reactions Weekly, 2022
  +7 more sources

Dupilumab‐induced Urticaria

Dermatologic Therapy, 2021
Mastorino L., Ortoncelli M., Virginia B., Rolla G., Avallone G., Cavaliere G., Riccardo V., Quaglino P., Ribero S.   +8 more
openaire   +3 more sources

Dupilumab

Reactions Weekly, 2021
  +5 more sources

Dupilumab

Reactions Weekly, 2019
  +6 more sources

Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis

New England Journal of Medicine, 2022
Matthew F Wipperman
exaly  

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

New England Journal of Medicine, 2023
Alberto A Papi, Eric Mortensen
exaly  

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma

New England Journal of Medicine, 2021
Alessandro Fiocchi, Asif H Khan, Naimish Patel   +2 more
exaly  

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

New England Journal of Medicine, 2021
Thomas Bieber, Jonathan I Silverberg, D Thaçi   +2 more
exaly  

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2022
exaly  

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

Nature Medicine, 2023
Sonja Ständer, John T O'malley
exaly